| [1] | WHO. WHO Coronavirus (COVID-19) Dashboard[EB/OL]. (2023-03)[2023-03-13]. https://covid19.who.int/. |
| [2] | WANG Y, ZHAO D Y, LIU X B, et al. Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants[J]. J Med Virol, 2023, 95(1):e28443. doi: 10.1002/jmv.28443 |
| [3] | 国家药品监督管理局. 国家药监局应急附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装进口注册[EB/OL]. (2023-02)[2023-03-13]. https://www.nmpa.gov.cn/directory/web/nmpa/yaowen/ypjgyw/20220212085753142.html. |
| [4] | ZHENG Q, MA P F, WANG M W, et al. Efficacy and safety of paxlovid for COVID-19: a meta-analysis[J]. J Infect, 2023, 86(1):66-117. |
| [5] | NAJJAR-DEBBINY R, GRONICH N, WEBER G, et al. Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients[J]. Clin Infect Dis, 2023, 76(3):e342-e349. doi: 10.1093/cid/ciac443 |
| [6] | 国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版)[EB/OL]. (2023-01)[2023-03-13]. http://www.nhc.gov.cn/xcs/zhengcwj/202301/32de5b2ff9bf4eaa88e75bdf7223a65a.shtml. |
| [7] | DE VRIES M, MOHAMED A S, PRESCOTT R A, et al. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19[J]. J Virol, 2021, 95(7):e01819-e01820. |
| [8] | MÓTYÁN J A, MAHDI M, HOFFKA G, et al. Potential resistance of SARS-CoV-2 main protease (mpro) against protease inhibitors: lessons learned from HIV-1 protease[J]. Int J Mol Sci, 2022, 23(7):3507. doi: 10.3390/ijms23073507 |
| [9] | HAMMOND J, LEISTER-TEBBE H, GARDNER A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19[J]. N Engl J Med, 2022, 386(15):1397-1408. doi: 10.1056/NEJMoa2118542 |
| [10] | WANG L, BERGER N A, DAVIS P B, et al. COVID-19 rebound after paxlovid and molnupiravir during January-June 2022[J]. medRxiv, 2022: 2022.06. 21.22276724. |
| [11] | WENG C Z, XIE R C, HAN G J, et al. Safety and efficacy of paxlovid against Omicron variants of coronavirus disease 2019 in elderly patients[J]. Infect Dis Ther, 2023, 12(2):649-662. doi: 10.1007/s40121-023-00760-x |
| [12] | 潘敏, 张田婧, 常双, 等. 老年人新型冠状病毒感染小分子抗病毒药物治疗建议[J/OL]. 中国药理学通报, 2023(3): 425-430(2023-03)[2023-03-14]. http://kns.cnki.net/kcms/detail/34.1086.r.20230308.1807.010.html. |
| [13] | PUHACH O, ADEA K, HULO N, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2[J]. Nat Med, 2022, 28(7):1491-1500. doi: 10.1038/s41591-022-01816-0 |
| [14] | WÖLFEL R, CORMAN V M, GUGGEMOS W, et al. Virological assessment of hospitalized patients with COVID-2019[J]. Nature, 2020, 581(7809):465-469. doi: 10.1038/s41586-020-2196-x |
| [15] | Ruirui, Wang. Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China[J]. Int J Infect Dis, 2020, 95:421-428. doi: 10.1016/j.ijid.2020.03.070 |